Join Skye Bioscience for a virtual KOL Event featuring Louis J. Aronne, MD, FACP (Weill Cornell Medicine), Marcus DaSilva Goncalves, MD, PhD (NYU Langone Health), Lee M. Kaplan, MD, PhD (Geisel School of Medicine at Dartmouth), and Beverly Tchang, MD (Weill Cornell Medicine), who will discuss the current treatment landscape for obesity, including the role of peripheral CB1 inhibition as a differentiated mechanism. Register at this link: https://bit.ly/4f1BMAh
Skye Bioscience Inc.
Biotechnology Research
San Diego, CA 1,932 followers
Unlocking the pharmaceutical potential of cannabinoids
About us
Skye Bioscience (Nasdaq: SKYE) is focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially through modulation of the CB1 receptor, to treat diseases with inflammatory, fibrotic, and metabolic processes.
- Website
-
http://www.skyebioscience.com
External link for Skye Bioscience Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- San Diego, CA
- Type
- Public Company
- Founded
- 2012
Locations
-
Primary
12250 El Camino Real Drive
Suite 100
San Diego, CA 92130, US
Employees at Skye Bioscience Inc.
Updates
-
Skye Bioscience Inc. reposted this
The event will focus on the scientific rationale for Skye’s Nimacimab peripheral CB1 inhibitor, the clinical experience, and the Phase 2 study design for Nimacimab as a monotherapy and in combination with a GLP-1R agonist. Dosing for the Phase 2 trial is expected to begin in Q3 2024. Read the full article here: https://bit.ly/45XSWdZ
-
-
The event will focus on the scientific rationale for Skye’s Nimacimab peripheral CB1 inhibitor, the clinical experience, and the Phase 2 study design for Nimacimab as a monotherapy and in combination with a GLP-1R agonist. Dosing for the Phase 2 trial is expected to begin in Q3 2024. Read the full article here: https://bit.ly/45XSWdZ
-
-
“We are honored to unite these world-class obesity experts as we continue to advance the clinical development of Nimacimab for the treatment of obesity,” said Punit Dhillon, Chief Executive Officer and Chairman of Skye. “Their extensive scientific and clinical expertise will be instrumental in providing strategic oversight to support Skye as we expand our operations. We look forward to leveraging their guidance as we prepare to progress Nimacimab into a Phase 2 trial this quarter.” Read the full article here: https://bit.ly/4czOJPT
-
-
Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership experience, complementing the Company’s operational and clinical expertise. Read the full article here: https://bit.ly/3LbCm0q
-
-
"We are pleased to be included in the Russell indexes, a widely recognized benchmark for small-cap stocks, which is a testament to Skye’s recent accomplishments,” said Kaitlyn Arsenault, CPA, CFO. Read the full article here: https://bit.ly/4cmCjLr
-
-
On Wednesday June 5th, Skye Bioscience's CSO Chris Twitty will present an overview of the company and its programs in obesity and glaucoma at the Jefferies Global Healthcare Conference 2024. You can listen to the webcast here: https://lnkd.in/g86ERASA
-
On Monday May 13th, Skye Bioscience's CEO and Chair Punit Dhillon will present an overview of the company at the Citizens JMP Securities Life Sciences Conference 2024. Listen live at 11:30 am ET or to the recording afterwards by registering here: https://lnkd.in/gDSZSds4
-
Skye is limitless and we are excited to announce we are growing our team 🚀 We are looking for a Senior Clinical Research Scientist to join our R&D team to help develop, plan and execute clinical biomarker studies. This person will be reporting to our Chief Scientific Officer, Chris Twitty, and be responsible for reviewing, analyzing and presenting clinical trial data from metabolic studies. This is an exciting time to join our fast growing team. Use the link below to apply! https://lnkd.in/gxg4T-ky